Celldom, Inc.
Biotechnology Research
San Carlos, California 2,404 followers
Find and study cells that make diseases incurable
Über uns
Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's cloneXplorer and proprietary nanowell plates uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.
- Website
-
http://www.celldom.com
External link for Celldom, Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 2-10 Mitarbeiter
- Hauptsitz
- San Carlos, California
- Typ
- In Privatbesitz
- Gegründet
- 2016
- Spezialitäten
- Single Cell Analysis, Quantitative Single Cell Analysis, Drug Discovery, Lead Optimization, Clinical Development, Biotechnology, Oncology, and Single Cell Genomics
Standorte
-
Primäre
Wegbeschreibung erhalten
733 Industrial Rd
San Carlos, California 94070, US
Employees at Celldom, Inc.
-
Ann L.
Experienced, creative, versatile Graphic Designer looking for *REMOTE* Part-Time, Freelance/Contract Graphic Design Work. Am willing to relocate to…
-
Guido Stadler
Director of Live Cell Biology
-
Oscar Neri
Manufacturing Engineer at Muwells Inc.
-
Lauren Holloway
Student at UBC Engineering Physics
Aktualisierungen
-
Cancer therapies frequently fail to cure patients due to resistant cell populations that survive drug treatments and evolve into resistant tumors. However, existing bulk analysis methods are unable to find these rare resistant cell populations within reasonable time scales (days), which both complicates researcher’s ability to study the underlying mechanisms of drug resistance, and also inhibits the clinician’s ability to tailor personalized therapeutic interventions. The Celldom platform can find drug resistant cells in days, as opposed to months, opens up new avenues for drug screening, allowing lead candidates to be tested not just for safety and efficacy, but also for therapeutic durability, which ultimately benefits both patients and insurers in their quest to develop more effective drugs. Learn more about Celldom's cloneXplorer platform in our white paper: https://lnkd.in/g7zDVMUg
-
-
We are making exceptional advances at Celldom, and now have the ability to identify and retrieve drug resistant cell lines in days rather than months. Here's an example of a MOLM-13 drug resistant clone that we retrieved after several days of continuous exposure to 5nM Quizartinib. This is one of 40 clones that we retrieved in a single experiment. If you would like to conduct an experiment with us, then please get in touch
-
Check out our amazing developments in retrieving live cells. https://lnkd.in/gPxr63Sf
And now for the finale...